Breakthrough Device Tag Validates Unmet Need, But Pilot-Only Evidence Leaves Approval Path Uncharted

FDA Grants Breakthrough Device Designation to Beyond Air's LungFit GO

Beyond Air, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation to its LungFit GO system for the treatment of nontuberculous mycobacterial pulmonary disease (NTM-PD). This designation underscores the significant unmet need in NTM-PD and is supported by clinical data from a pilot study published in *Annals of the American Thoracic Society*. The study showed that adult patients with chronic refractory NTM lung disease could safely self-administer high-dose intermittent inhaled nitric oxide therapy at home, demonstrating high treatment compliance, a favorable safety profile, and signs of improved quality-of-life and reduced mycobacterial burden, including culture conversion. The designation is expected to streamline the device's clinical development and regulatory review process.

• The Breakthrough Device Designation for LungFit GO is strongly supported by encouraging clinical data from a pilot study, which was published in the peer-reviewed journal Annals of the American Thoracic Society. This study demonstrated that adult subjects with chronic refractory NTM lung disease were able to safely self-administer high-dose intermittent inhaled nitric oxide therapy at home, achieving high treatment compliance and a favorable safety profile.
• LungFit GO represents a novel, portable, and cylinder-free home-based treatment platform for NTM-PD, a rare and serious chronic bacterial lung infection. NTM-PD is associated with substantial morbidity and mortality, often requiring prolonged, difficult-to-tolerate multidrug antibiotic regimens with limited success, highlighting a significant unmet medical need that LungFit GO aims to address.
• The FDA's Breakthrough Device Designation validates the significant unmet need facing patients with NTM-PD and the encouraging clinical experience generated with LungFit GO. This designation provides Beyond Air with enhanced interactions with the FDA, which is anticipated to streamline the clinical development process and support more efficient advancement of the program toward potential regulatory approval.

Addressing the Significant Unmet Need in NTM-PD Treatment

Current treatment regimens for NTM-PD face substantial obstacles that limit their clinical effectiveness across both Mycobacterium avium complex (MAC) and Mycobacterium abscessus complex (MABC) disease. Despite decades of therapeutic development, treatment success rates remain suboptimal and recurrence is common, underscoring a significant unmet need in this disease area.

• Low treatment success and high recurrence rates: For MAC pulmonary disease, treatment success rates are only roughly 60%, and over 30% of patients experience recurrence. Recurrence is often attributable to reinfection rather than relapse, meaning that even successful culture conversion does not reliably prevent future disease episodes.

• Poor tolerability and adverse events from standard regimens: The standard three-drug regimen — macrolide, rifampin, and ethambutol — is poorly tolerated. Long-term ethambutol administration leads to permanent discontinuation in a subset of patients, most commonly due to ocular toxicity. Among patients who discontinue ethambutol, treatment failure rates are higher than in those who complete the standard regimen, and substitution with later-generation fluoroquinolone is associated with a statistically significantly higher failure rate (39.1% vs. 19.3%, P = .045).

• Macrolide resistance in M. abscessus: Macrolide resistance has a profoundly negative impact on M. abscessus treatment response. Subspecies abscessus and bolletii carry an inducible macrolide resistance gene [erm(41)], resulting in clinical macrolide resistance, while acquired mutational macrolide resistance poses an additional threat. Preserving macrolide susceptibility is among the highest treatment priorities, yet macrolide-resistant M. abscessus disease is not predictably managed even with more aggressive therapy.

• Limited validated antimicrobials and prolonged diagnostic timelines: Aside from macrolides and amikacin, no other antibiotics have a validated minimum inhibitory concentration for M. abscessus. Current growth-based drug susceptibility testing takes 7 to 14 days to identify clarithromycin susceptibility due to inducible macrolide resistance, delaying prompt clinical management.

• Surgical resection does not prevent recurrence: Adjunctive lung resection achieves culture conversion in approximately 90% of eligible patients, but recurrence occurs in 33% of those who convert, with 49% of recurrence cases attributed to reinfection by different NTM species or subspecies. Surgery therefore reduces bacterial burden and manages symptoms but does not eliminate the risk of future disease.

• Higher mortality in MABC-PD despite comparable surgical outcomes: Although treatment outcomes after adjunctive lung resection did not significantly differ between MAC and MABC groups overall, mortality was significantly higher in the MABC-PD group than the MAC-PD group (7/35 vs. 4/90, P = .006), reflecting the inherently more refractory nature of M. abscessus infection.

LungFit GO's Pilot Study: Safety, Compliance, and Early Efficacy

Several recent studies have evaluated therapeutic interventions for nontuberculous mycobacterial pulmonary disease (NTM-PD), with amikacin liposome inhalation suspension (ALIS) featuring prominently across the evidence base. The pivotal CONVERT trial — a prospective, open-label, randomized study — assessed daily ALIS (590 mg) added to standard guideline-based therapy (GBT) versus GBT alone in adults with treatment-refractory Mycobacterium avium complex (MAC) lung disease. Culture conversion by Month 6 was achieved in 29.0% of patients receiving ALIS + GBT versus 8.9% with GBT alone (odds ratio, 4.22; 95% confidence interval, 2.08–8.57; P < 0.001). Respiratory adverse events — primarily dysphonia, cough, and dyspnea — were reported in 87.4% of the ALIS + GBT arm versus 50.0% with GBT alone, while serious treatment-emergent adverse events occurred in 20.2% and 17.9% of patients, respectively. A separate open-label trial examining ALIS in Mycobacterium abscessus pulmonary disease demonstrated that 50% of patients with evaluable longitudinal microbiologic data achieved sputum culture conversion to negative findings, with 67% of converters sustaining conversion through Month 12. Notably, mutational amikacin resistance emerged in 18% of patients, all of whom were receiving clofazimine or clofazimine plus azithromycin as companion medications. Dose reduction to three times weekly was common, occurring in 52% of patients.

Real-world evidence has further characterized ALIS performance outside controlled trial settings. A retrospective, observational study of 12 patients with refractory MAC pulmonary disease reported that three of nine patients who continued treatment for at least six months achieved culture conversion, all exhibiting the nodular bronchiectatic radiographic pattern. Adverse events included hoarseness in eight patients, fever and bronchospasm leading to discontinuation in two, and hearing impairment or dizziness in two. A separate single-center retrospective analysis of 27 patients with refractory MAC pulmonary disease treated with ALIS for a median of 14.6 months reported a sputum culture conversion rate of 51.8% (95% CI, 34.0–69.3%). Cavitary lesions, prior aminoglycoside use, and inappropriate ALIS administration — including prolonged intermittent use and inadequate nebulizer handset replacement — were significantly associated with non-conversion. Dysphonia was the most frequent adverse event and occasionally led to prolonged intermittent use of ALIS, while ALIS-related lung abnormalities on computed tomography scans were observed in 21 of 26 patients.

Beyond ALIS, two additional agents have been studied as adjunctive therapies in NTM-PD. A prospective cohort study evaluated a nine-month oral linezolid regimen in 40 adults with NTM diseases associated with anti-interferon gamma autoantibodies. By Month 9, the cumulative incidence rates of relapse and treatment failure were 22.5% and 15.0%, respectively, with 25% of patients discontinuing early due to adverse events; anemia and peripheral neuropathy were the most frequent. A retrospective cohort study of sitafloxacin-containing regimens in 50 patients with MAC pulmonary disease demonstrated modest outcomes, with fewer than 20% of patients achieving radiologic, symptomatic, or microbiological improvement across all patient groups at six months. The two patients who achieved culture conversion had clarithromycin-susceptible strains, non-cavitary disease, and received concomitant ethambutol.

Beyond NTM-PD: The Broader Potential of Nitric Oxide

Nitric oxide (NO) is being investigated across a broad range of indications beyond NTM-PD, spanning infectious, cardiovascular, respiratory, and surgical contexts. The intervention models vary considerably, from in vitro and animal studies through to phase I and phase III randomized controlled trials.

Breakthrough Designation: Reshaping NTM-PD Treatment with Home-Based iNO

The recent Breakthrough Device Designation for Beyond Air's LungFit GO system for nontuberculous mycobacterial pulmonary disease (NTM-PD) signals a potentially transformative moment for patients grappling with this chronic and often debilitating infection. NTM-PD presents a significant unmet medical need, with current treatment relying on prolonged, multi-drug antibiotic regimens that are frequently associated with severe toxicities, poor adherence, and a substantial impact on patient quality of life. The recognition by the FDA underscores the urgency for more effective and tolerable therapeutic options.

Inhaled nitric oxide (iNO) has long been recognized for its antimicrobial properties, with studies indicating its potential to reduce bacterial burden and even achieve culture conversion in various infections. What makes LungFit GO particularly innovative is its ability to deliver high-dose intermittent iNO therapy safely in a home setting. This represents a crucial shift from the traditional acute care applications of iNO, such as in pulmonary hypertension or acute lung injury, to a chronic, patient-centric model. The strategic implications are clear:

• Accelerated Market Access: The Breakthrough Device status will likely expedite the regulatory review process, potentially bringing this much-needed therapy to patients faster.

• Enhanced Patient Experience: Home administration could significantly improve patient convenience, adherence, and overall quality of life, moving treatment out of the hospital and into the daily lives of patients.

• Platform Validation: Success in NTM-PD could validate the home-based iNO delivery platform for other chronic respiratory conditions where iNO's antimicrobial or anti-inflammatory effects might be beneficial.

However, several risks must be carefully considered. While pilot data are encouraging, the existing evidence for non-antibiotic NTM therapies, including iNO, is currently of 'very low-certainty' from non-randomized studies. Therefore, robust, randomized clinical trials will be essential to definitively establish long-term efficacy and durability of response. Furthermore, while iNO is generally safe in acute settings, chronic, high-dose self-administration at home introduces new considerations for long-term safety, including potential adverse events like methemoglobinemia or nitrogen dioxide exposure, and the need for effective patient monitoring and education. Finally, despite the designation, securing broad physician adoption and favorable reimbursement for a novel, non-antibiotic device-based therapy will require compelling clinical and health economic evidence to overcome the inertia of established, albeit imperfect, antibiotic regimens. This development opens a promising new chapter, but the journey to widespread clinical integration will depend on rigorous data and strategic execution.